Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.

Therapeutic drug monitoring - 1 Aug 2017

Li Zi-Wei, Peng Feng-Hua, Yan Miao, Liang Wu, Liu Xiao-Lei, Wu Yan-Qin, Lin Xiao-Bin, Tan Sheng-Lan, Wang Feng, Xu Ping, Fang Ping-Fei, Liu Yi-Ping, Xiang Da-Xiong, Zhang Bi-Kui

Abstract excerpt

BACKGROUND: Invasive fungal infection (IFI) is one of the leading causes of early death after renal transplantation. Voriconazole (VRC) is the first-line drug of IFI. Because of the large inter- and intraindividual variability in VRC plasma concentrations and the narrow therapeutic window for treating patients with IFIs, it is crucial to study the factors which could influence pharmacokinetic variability. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2C19
Share to Antifungal Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Transplantation

Share to Postoperative Complications

Share to Transplant Recipients

Share to Voriconazole

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 28604474
DOI: 10.1097/FTD.0000000000000425
PMCID: PMC5538305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.PMID 28604474Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients.Semantic proximity Read ↗

Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infectionsSemantic proximity Read ↗

Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.Semantic proximity Read ↗

Predictors of tacrolimus dose optimization when drug-drug interaction associated with voriconazole in heart transplant recipientsSemantic proximity Read ↗

A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.Semantic proximity Read ↗

The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.Semantic proximity Read ↗

Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.Semantic proximity Read ↗

Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.Semantic proximity Read ↗

Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimenSemantic proximity Read ↗

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.